Pyxis Oncology, Inc. (PYXS)
1.86
+0.18
(+10.71%)
USD |
NASDAQ |
Nov 20, 12:16
Pyxis Oncology Free Cash Flow : -70.93M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -70.93M |
| June 30, 2026 | -67.92M |
| March 31, 2026 | -66.98M |
| December 31, 2025 | -63.51M |
| September 30, 2025 | -72.45M |
| June 30, 2025 | -73.82M |
| March 31, 2025 | -59.50M |
| December 31, 2024 | -57.91M |
| September 30, 2024 | -53.79M |
| Date | Value |
|---|---|
| June 30, 2024 | -56.79M |
| March 31, 2024 | -67.14M |
| December 31, 2023 | -77.44M |
| September 30, 2023 | -81.43M |
| June 30, 2023 | -88.60M |
| March 31, 2023 | -99.16M |
| December 31, 2022 | -95.73M |
| September 30, 2022 | -88.66M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Cypherpunk Technologies, Inc. | -132.19M |
| Cue Biopharma, Inc. | -51.22M |
| Yarrow Bioscience, Inc. | -99.79M |
| Faeth Therapeutics, Inc. | -43.28M |
| Indaptus Therapeutics, Inc. | -13.97M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -16.29M |
| Cash from Investing (Quarterly) | -37.29M |
| Cash from Financing (Quarterly) | 38.58M |
| Free Cash Flow Per Share (Quarterly) | -0.1951 |
| Free Cash Flow to Equity (Quarterly) | -15.86M |
| Free Cash Flow to Firm (Quarterly) | -16.29M |
| Free Cash Flow Yield | -45.66% |